Ginkgo Bioworks Holdings Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jason Kelly
Chief executive officer
US$262.5k
Total compensation
| CEO salary percentage | 95.2% |
| CEO tenure | 16.3yrs |
| CEO ownership | 4.3% |
| Management average tenure | 5.5yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06
With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12Ginkgo Bioworks launches Ginkgo Enzyme Services
Dec 08Ginkgo, Lygos team up to produce sustainable biobased specialty chemicals
Nov 11Ginkgo, Draper develop new technologies to detect engineered DNA
Oct 17Ginkgo stock rises on acquisition of French biotech Altar
Oct 04Ginkgo Bioworks: Promising Upside But Not Without Risks
Sep 28Ginkgo Bioworks: May The Ginkgo King Grow
Sep 13Is There An Opportunity With Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 50% Undervaluation?
Aug 26Gingko Bioworks: Near-Term Challenges Trump Downstream Economics
Aug 17Ginkgo Bioworks: Time To Buy
Aug 10Biotech Zymergen surges 21% on $300M buyout deal with Ginkgo
Jul 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$893m |
| Sep 30 2023 | n/a | n/a | -US$857m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | n/a | n/a | -US$2b |
| Dec 31 2022 | US$263k | US$250k | -US$2b |
| Sep 30 2022 | n/a | n/a | -US$4b |
| Jun 30 2022 | n/a | n/a | -US$3b |
| Mar 31 2022 | n/a | n/a | -US$2b |
| Dec 31 2021 | US$381m | US$250k | -US$2b |
| Sep 30 2021 | n/a | n/a | -US$276m |
| Jun 30 2021 | n/a | n/a | -US$200m |
| Mar 31 2021 | n/a | n/a | -US$175m |
| Dec 31 2020 | US$11m | US$250k | -US$127m |
Compensation vs Market: Jason's total compensation ($USD262.50K) is below average for companies of similar size in the US market ($USD5.52M).
Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.
CEO
Jason Kelly (41 yo)
16.3yrs
Tenure
US$262,500
Compensation
Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly Founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) since 2008 and serves as its Chief Executive Officer and has served as Di...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | US$262.50k | 4.28% $ 79.3m | |
| Founder | no data | US$262.50k | 4.65% $ 86.1m | |
| Chief Financial Officer | 3.4yrs | US$2.20m | 0.075% $ 1.4m | |
| Founder | no data | no data | 1.74% $ 32.2m | |
| Founder | no data | no data | 4.79% $ 88.7m | |
| Founder | no data | no data | 4.64% $ 85.9m | |
| Chief Accounting Officer | less than a year | no data | no data | |
| General Counsel & Secretary | no data | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Head of People | 6.3yrs | no data | no data | |
| Head of Design | 5.5yrs | no data | no data | |
| Head of Omics & Analytical Chemistry | 5.8yrs | no data | no data |
5.5yrs
Average Tenure
41yo
Average Age
Experienced Management: DNA's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16.3yrs | US$262.50k | 4.28% $ 79.3m | |
| Founder | 16.3yrs | US$262.50k | 4.65% $ 86.1m | |
| Director | 5yrs | US$595.60k | 0.10% $ 1.9m | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Independent Director | 2.6yrs | US$566.01k | 0.021% $ 389.1k | |
| Independent Director | 7.3yrs | US$583.51k | 0.062% $ 1.1m | |
| Independent Director | 1.7yrs | US$1.01m | 0.00025% $ 4.6k | |
| Independent Director | 2.6yrs | US$563.51k | 0.029% $ 545.1k | |
| Independent Chairman of the Board | 9.3yrs | US$584.73k | 0.083% $ 1.5m | |
| Independent Director | 2.6yrs | US$564.96k | 0.0040% $ 74.6k | |
| Member of Biopharma Advisory Board | less than a year | no data | no data |
2.6yrs
Average Tenure
61yo
Average Age
Experienced Board: DNA's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.